What it sells
A Disease Focused Biotech, Building Multiple Billion Dollar Drugs
Business model breakdown
Workflow: what inputs become what output?
Validate modalities in disease models that translate to patients, then take focused capital to the clinic; first indication Rett Syndrome.
Economics: what it saves and how it charges
Drug development biotech; no revenue stated. Policy caps indirect costs at 15% of MTDC on sponsored research agreements with partner institutions.
Distribution: how it reaches customers
Sponsored research agreements with partner institutions; contact by email.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2025 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.